

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
ANY EVENT	ANY EVENT	69 (80%)	86 (90%)	70 (97%)	225 (89%)
CARDIAC DISORDERS	ANY EVENT	13 (15%)	16 (17%)	15 (21%)	44 (17%)
	ATRIAL FIBRILLATION	1 (1%)	2 (2%)	2 (3%)	5 (2%)
	ATRIAL FLUTTER	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	ATRIAL HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	ATRIOVENTRICULAR BLOCK	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	FIRST DEGREE				
	ATRIOVENTRICULAR BLOCK	2 (2%)	2 (2%)	1 (1%)	5 (2%)
	SECOND DEGREE				
	BRADYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BUNDLE BRANCH BLOCK LEFT	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BUNDLE BRANCH BLOCK RIGHT	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	CARDIAC DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	CARDIAC FAILURE CONGESTIVE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	MYOCARDIAL INFARCTION	4 (5%)	2 (2%)	4 (6%)	10 (4%)
	PALPITATIONS	0 (0%)	2 (2%)	0 (0%)	2 (1%)
	SINUS ARRHYTHMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	SINUS BRADYCARDIA	2 (2%)	7 (7%)	8 (11%)	17 (7%)
	SUPRAVENTRICULAR				
	EXTRASYSTOLES				
	SUPRAVENTRICULAR	1 (1%)	1 (1%)	1 (1%)	3 (1%)
	TACHYCARDIA				
	TACHYCARDIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
		1 (1%)	0 (0%)	0 (0%)	1 (0%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline	Xanomeline	Total (N=254)
		n	(%)	Low Dose (N=96)	High Dose (N=72)	
CARDIAC DISORDERS	VENTRICULAR EXTRASYSTOLES	0	(0%)	2	(2%)	1 (1%)
	VENTRICULAR HYPERTROPHY	1	(1%)	0	(0%)	0 (0%)
	WOLFF-PARKINSON-WHITE SYNDROME	0	(0%)	1	(1%)	0 (0%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	ANY EVENT	0	(0%)	1	(1%)	2 (3%)
	VENTRICULAR SEPTAL DEFECT	0	(0%)	1	(1%)	2 (3%)
EAR AND LABYRINTH DISORDERS	ANY EVENT	1	(1%)	2	(2%)	1 (1%)
	CERUMEN IMPACTION	0	(0%)	1	(1%)	0 (0%)
	EAR PAIN	1	(1%)	0	(0%)	0 (0%)
	TINNITUS	0	(0%)	1	(1%)	0 (0%)
	VERTIGO	0	(0%)	1	(1%)	1 (1%)
EYE DISORDERS	ANY EVENT	4	(5%)	2	(2%)	1 (1%)
	CONJUNCTIVAL HAEMORRHAGE	0	(0%)	1	(1%)	0 (0%)
	CONJUNCTIVITIS	2	(2%)	0	(0%)	0 (0%)
	EYE ALLERGY	1	(1%)	0	(0%)	0 (0%)
	EYE PRURITUS	1	(1%)	0	(0%)	0 (0%)
	EYE SWELLING	1	(1%)	0	(0%)	0 (0%)
	GLAUCOMA	1	(1%)	0	(0%)	1 (1%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)			
		n	(%)	Low Dose (N=96)	High Dose (N=72)				
EYE DISORDERS	VISION BLURRED	0	(0%)	1	(1%)	1	(1%)	2	(1%)
GASTROINTESTINAL DISORDERS	ANY EVENT	17	(20%)	16	(17%)	20	(28%)	53	(21%)
	ABDOMINAL DISCOMFORT	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	ABDOMINAL PAIN	1	(1%)	3	(3%)	1	(1%)	5	(2%)
	CONSTIPATION	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	DIARRHOEA	9	(10%)	6	(6%)	3	(4%)	18	(7%)
	DYSPEPSIA	1	(1%)	1	(1%)	1	(1%)	3	(1%)
	DYSPHAGIA	0	(0%)	1	(1%)	0	(0%)	1	(0%)
	FLATULENCE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GASTROINTESTINAL	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	HAEMORRHAGE								
	GASTROOESOPHAGEAL REFLUX	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	DISEASE								
	GLOSSITIS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	HIATUS HERNIA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	NAUSEA	3	(3%)	3	(3%)	6	(8%)	12	(5%)
	RECTAL HAEMORRHAGE	0	(0%)	1	(1%)	0	(0%)	1	(0%)
	SALIVARY HYPERSECRETION	0	(0%)	0	(0%)	4	(6%)	4	(2%)
	STOMACH DISCOMFORT	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	VOMITING	3	(3%)	4	(4%)	6	(8%)	13	(5%)

- 1.) Only treatment emergent events related to lipids are displayed.
 2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Xanomeline		Xanomeline		Total (N=254)
		Placebo (N=86) n (%)	Low Dose (N=96) n (%)	High Dose (N=72) n (%)	n (%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ANY EVENT	21 (24%)	51 (53%)	36 (50%)	108 (43%)	
	APPLICATION SITE BLEEDING	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	APPLICATION SITE DERMATITIS	5 (6%)	9 (9%)	7 (10%)	21 (8%)	
	APPLICATION SITE DESQUAMATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	APPLICATION SITE DISCHARGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
	APPLICATION SITE DISCOLOURATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	APPLICATION SITE ERYTHEMA	3 (3%)	13 (14%)	14 (19%)	30 (12%)	
	APPLICATION SITE INDURATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
	APPLICATION SITE IRRITATION	3 (3%)	9 (9%)	9 (12%)	21 (8%)	
	APPLICATION SITE PAIN	0 (0%)	0 (0%)	2 (3%)	2 (1%)	
	APPLICATION SITE PERSPIRATION	0 (0%)	0 (0%)	2 (3%)	2 (1%)	
	APPLICATION SITE PRURITUS	6 (7%)	23 (24%)	21 (29%)	50 (20%)	
	APPLICATION SITE REACTION	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
	APPLICATION SITE SWELLING	0 (0%)	1 (1%)	2 (3%)	3 (1%)	
	APPLICATION SITE URTICARIA	0 (0%)	2 (2%)	1 (1%)	3 (1%)	
	APPLICATION SITE VESICLES	1 (1%)	5 (5%)	5 (7%)	11 (4%)	
	APPLICATION SITE WARMTH	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	ASTHENIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
	CHEST DISCOMFORT	0 (0%)	1 (1%)	1 (1%)	2 (1%)	
	CHEST PAIN	0 (0%)	0 (0%)	2 (3%)	2 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.
 2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)
		n	(%)	Low Dose (N=96)	High Dose (N=72)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CHILLS	1	(1%)	1	(1%)	3 (1%)
	CYST	0	(0%)	1	(1%)	1 (0%)
	FATIGUE	1	(1%)	5	(5%)	11 (4%)
	FEELING ABNORMAL	0	(0%)	0	(0%)	1 (0%)
	FEELING COLD	0	(0%)	0	(0%)	1 (0%)
	INFLAMMATION	0	(0%)	1	(1%)	1 (0%)
	MALAISE	0	(0%)	1	(1%)	3 (1%)
	OEDEMA	0	(0%)	2	(2%)	2 (1%)
	OEDEMA PERIPHERAL	2	(2%)	1	(1%)	5 (2%)
	PAIN	0	(0%)	1	(1%)	2 (1%)
	PYREXIA	2	(2%)	1	(1%)	3 (1%)
	SECRETION DISCHARGE	0	(0%)	1	(1%)	1 (0%)
	SUDDEN DEATH	0	(0%)	1	(1%)	1 (0%)
	SWELLING	0	(0%)	1	(1%)	1 (0%)
	ULCER	0	(0%)	1	(1%)	1 (0%)
HEPATOBILIARY DISORDERS	ANY EVENT	1	(1%)	0	(0%)	1 (0%)
	HYPERBILIRUBINAEMIA	1	(1%)	0	(0%)	1 (0%)
IMMUNE SYSTEM DISORDERS	ANY EVENT	0	(0%)	1	(1%)	2 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.
 2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline	Xanomeline	Total (N=254)
		n	(%)	Low Dose (N=96)	High Dose (N=72)	
IMMUNE SYSTEM DISORDERS	HYPERSENSITIVITY	0	(0%)	1	(1%)	0 (0%)
	SEASONAL ALLERGY	0	(0%)	0	(0%)	1 (1%)
INFECTIONS AND INFESTATIONS	ANY EVENT	16	(19%)	10	(10%)	13 (18%)
	BRONCHITIS	1	(1%)	0	(0%)	0 (0%)
	CELLULITIS	0	(0%)	1	(1%)	0 (0%)
	CERVICITIS	1	(1%)	0	(0%)	0 (0%)
	CYSTITIS	1	(1%)	0	(0%)	1 (1%)
	EAR INFECTION	2	(2%)	0	(0%)	0 (0%)
	GASTROENTERITIS VIRAL	1	(1%)	0	(0%)	0 (0%)
	HORDEOLUM	0	(0%)	0	(0%)	1 (1%)
	INFLUENZA	1	(1%)	1	(1%)	1 (1%)
	LOCALISED INFECTION	1	(1%)	1	(1%)	0 (0%)
	LOWER RESPIRATORY TRACT	0	(0%)	0	(0%)	1 (1%)
	INFECTION					
	NASOPHARYNGITIS	2	(2%)	4	(4%)	6 (8%)
	ONYCHOMYCOSIS	0	(0%)	1	(1%)	0 (0%)
	PNEUMONIA	0	(0%)	1	(1%)	0 (0%)
	RHINITIS	0	(0%)	0	(0%)	1 (1%)
	UPPER RESPIRATORY TRACT	6	(7%)	1	(1%)	3 (4%)
	INFECTION					
	URINARY TRACT INFECTION	2	(2%)	0	(0%)	1 (1%)
						3 (1%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline	Xanomeline	Total (N=254)
		n	(%)	Low Dose (N=96)	High Dose (N=72)	
INFECTIONS AND INFESTATIONS	VAGINAL MYCOSIS	1	(1%)	0	(0%)	0
	VIRAL INFECTION	0	(0%)	1	(1%)	0
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ANY EVENT	4	(5%)	5	(5%)	5
	CONTUSION	1	(1%)	1	(1%)	2
	EXCORIATION	2	(2%)	1	(1%)	1
	FACIAL BONES FRACTURE	0	(0%)	0	(0%)	1
	FALL	1	(1%)	2	(2%)	1
	HIP FRACTURE	1	(1%)	0	(0%)	2
	JOINT DISLOCATION	0	(0%)	1	(1%)	0
	SKIN LACERATION	1	(1%)	2	(2%)	0
	WOUND	0	(0%)	1	(1%)	0
						1
INVESTIGATIONS	ANY EVENT	10	(12%)	8	(8%)	5
	BIOPSY	0	(0%)	0	(0%)	1
	BIOPSY PROSTATE	0	(0%)	0	(0%)	1
	BLOOD ALKALINE PHOSPHATASE INCREASED	1	(1%)	0	(0%)	0
	BLOOD CHOLESTEROL INCREASED	0	(0%)	0	(0%)	1
	BLOOD CREATINE PHOSPHOKINASE INCREASED	1	(1%)	0	(0%)	0
	BLOOD GLUCOSE INCREASED	0	(0%)	1	(1%)	1
						0

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Xanomeline		Xanomeline		Total (N=254)
		Placebo (N=86)	Low Dose (N=96)	High Dose (N=72)	n (%)	
INVESTIGATIONS	BLOOD URINE PRESENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
	BODY TEMPERATURE INCREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	CYSTOSCOPY	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
	ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4 (5%)	1 (1%)	0 (0%)	5 (2%)	
	ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
	ELECTROCARDIOGRAM T WAVE INVERSION	2 (2%)	1 (1%)	1 (1%)	4 (2%)	
	HEART RATE INCREASED	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
	HEART RATE IRREGULAR	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
	NASAL MUCOSA BIOPSY	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	NEUTROPHIL COUNT INCREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	URINE ANALYSIS ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	WEIGHT DECREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
	WHITE BLOOD CELL COUNT INCREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
METABOLISM AND NUTRITION DISORDERS	ANY EVENT	6 (7%)	1 (1%)	3 (4%)	10 (4%)	
	DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
	DEHYDRATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
	DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
	FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
	HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline	Xanomeline	Total (N=254)
		n	(%)	Low Dose (N=96)	High Dose (N=72)	
METABOLISM AND NUTRITION DISORDERS	HYPONATRAEMIA	1	(1%)	0	(0%)	0
	INCREASED APPETITE	1	(1%)	0	(0%)	1
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	ANY EVENT	5	(6%)	7	(7%)	8
	ARTHRALGIA	1	(1%)	2	(2%)	1
	ARTHRITIS	1	(1%)	0	(0%)	1
	BACK PAIN	1	(1%)	1	(1%)	3
	FLANK PAIN	0	(0%)	0	(0%)	2
	MUSCLE SPASMS	0	(0%)	1	(1%)	1
	MUSCULAR WEAKNESS	0	(0%)	1	(1%)	0
	MYALGIA	0	(0%)	0	(0%)	1
	PAIN IN EXTREMITY	1	(1%)	0	(0%)	0
	SHOULDER PAIN	1	(1%)	2	(2%)	0
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ANY EVENT	0	(0%)	2	(2%)	1
	COLON CANCER	0	(0%)	1	(1%)	0
	MALIGNANT FIBROUS	0	(0%)	1	(1%)	0
	HISTIOTICOMA					
	PROSTATE CANCER	0	(0%)	0	(0%)	1
NERVOUS SYSTEM DISORDERS	ANY EVENT	12	(14%)	22	(23%)	25
1.) Only treatment emergent events related to lipids are displayed.		25 (35%)				
2.) Subjects are only counted once within each body system and preferred term.		59 (23%)				

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)	Xanomeline	Xanomeline	Total (N=254)
			Low Dose (N=96)	High Dose (N=72)	
NERVOUS SYSTEM DISORDERS	AMNESIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BALANCE DISORDER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	BURNING SENSATION	0 (0%)	0 (0%)	2 (3%)	2 (1%)
	COGNITIVE DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	COMPLEX PARTIAL SEIZURES	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	COORDINATION ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	DIZZINESS	2 (2%)	9 (9%)	11 (15%)	22 (9%)
	HEADACHE	7 (8%)	3 (3%)	6 (8%)	16 (6%)
	HEMIANOPIA HOMONYMOUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	HYPERSOMNIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	LETHARGY	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	PARAESTHESIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	PARAESTHESIA ORAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	PARKINSON'S DISEASE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PAROSMIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	PSYCHOMOTOR HYPERACTIVITY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	SOMNOLENCE	2 (2%)	3 (3%)	1 (1%)	6 (2%)
	STUPOR	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	SYNCOPE	0 (0%)	5 (5%)	2 (3%)	7 (3%)

- 1.) Only treatment emergent events related to lipids are displayed.
 2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)
		n	(%)	Low Dose (N=96)	High Dose (N=72)	
NERVOUS SYSTEM DISORDERS	SYNCOPE VASOVAGAL	0	(0%)	0	(0%)	1 (1%)
	TRANSIENT ISCHAEMIC ATTACK	0	(0%)	2	(2%)	1 (1%)
PSYCHIATRIC DISORDERS	ANY EVENT	10	(12%)	11	(11%)	29 (11%)
	AGITATION	2	(2%)	3	(3%)	0 (0%)
	ANXIETY	1	(1%)	3	(3%)	0 (0%)
	COMPLETED SUICIDE	1	(1%)	0	(0%)	0 (0%)
	CONFUSIONAL STATE	2	(2%)	3	(3%)	1 (1%)
	DELIRIUM	0	(0%)	0	(0%)	1 (1%)
	DELUSION	1	(1%)	0	(0%)	1 (1%)
	DEPRESSED MOOD	0	(0%)	1	(1%)	1 (1%)
	DISORIENTATION	1	(1%)	0	(0%)	0 (0%)
	HALLUCINATION	0	(0%)	0	(0%)	1 (1%)
	HALLUCINATION, VISUAL	0	(0%)	0	(0%)	1 (1%)
	INSOMNIA	2	(2%)	0	(0%)	2 (3%)
	IRRITABILITY	1	(1%)	1	(1%)	0 (0%)
	LIBIDO DECREASED	0	(0%)	0	(0%)	1 (1%)
	LISTLESS	0	(0%)	0	(0%)	1 (1%)
	NIGHTMARE	0	(0%)	0	(0%)	1 (1%)
	RESTLESSNESS	0	(0%)	1	(1%)	0 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)	Xanomeline	Xanomeline	Total (N=254)
			Low Dose (N=96)	High Dose (N=72)	
PSYCHIATRIC DISORDERS					
RENAL AND URINARY DISORDERS	ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)
	CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)
	NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)
	POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	ANY EVENT	2 (2%)	0 (0%)	1 (1%)	3 (1%)
	BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)
	PELVIC PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ANY EVENT	10 (12%)	10 (10%)	10 (14%)	30 (12%)
	ALLERGIC GRANULOMATOUS ANGIITIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	COUGH	3 (3%)	6 (6%)	5 (7%)	14 (6%)
	DYSPHONIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	DYSPNOEA	1 (1%)	1 (1%)	1 (1%)	3 (1%)
	EMPHYSEMA	1 (1%)	0 (0%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
 2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)
		n	(%)	Low Dose (N=96)	High Dose (N=72)	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	EPISTAXIS	0	(0%)	1	(1%)	2 (3%)
	HAEMOPTYSIS	1	(1%)	0	(0%)	1 (0%)
	NASAL CONGESTION	3	(3%)	1	(1%)	3 (4%)
	PHARYNGEAL ERYTHEMA	0	(0%)	0	(0%)	1 (1%)
	PHARYNGOLARYNGEAL PAIN	0	(0%)	1	(1%)	2 (1%)
	POSTNASAL DRIP	1	(1%)	0	(0%)	1 (0%)
	PRODUCTIVE COUGH	0	(0%)	0	(0%)	1 (0%)
	RALES	1	(1%)	0	(0%)	0 (0%)
	RESPIRATORY TRACT CONGESTION	0	(0%)	0	(0%)	1 (1%)
	RHINORRHOEA	0	(0%)	1	(1%)	2 (1%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ANY EVENT	21	(24%)	42	(44%)	42 (58%)
	ACTINIC KERATOSIS	0	(0%)	0	(0%)	1 (1%)
	ALOPECIA	1	(1%)	0	(0%)	0 (0%)
	BLISTER	0	(0%)	5	(5%)	1 (1%)
	COLD SWEAT	1	(1%)	0	(0%)	0 (0%)
	DERMATITIS ATOPIC	1	(1%)	0	(0%)	0 (0%)
	DERMATITIS CONTACT	0	(0%)	1	(1%)	1 (0%)
	DRUG ERUPTION	1	(1%)	0	(0%)	0 (0%)
	ERYTHEMA	9	(10%)	15	(16%)	14 (19%)
						38 (15%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)
		n	(%)	n	(%)	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	HYPERHIDROSIS	2	(2%)	4	(4%)	8 (11%)
	PRURITUS	8	(9%)	23	(24%)	26 (36%)
	PRURITUS GENERALISED	0	(0%)	1	(1%)	1 (1%)
	RASH	5	(6%)	13	(14%)	11 (15%)
	RASH ERYTHEMATOUS	0	(0%)	2	(2%)	0 (0%)
	RASH MACULO-PAPULAR	0	(0%)	0	(0%)	1 (1%)
	RASH PAPULAR	0	(0%)	0	(0%)	1 (1%)
	RASH PRURITIC	0	(0%)	1	(1%)	2 (3%)
	SKIN EXFOLIATION	0	(0%)	1	(1%)	0 (0%)
	SKIN IRRITATION	3	(3%)	6	(6%)	5 (7%)
	SKIN ODOUR ABNORMAL	0	(0%)	0	(0%)	1 (1%)
	SKIN ULCER	1	(1%)	0	(0%)	0 (0%)
	URTICARIA	0	(0%)	1	(1%)	1 (1%)
SOCIAL CIRCUMSTANCES	ANY EVENT	0	(0%)	0	(0%)	1 (1%)
	ALCOHOL USE	0	(0%)	0	(0%)	1 (1%)
SURGICAL AND MEDICAL PROCEDURES	ANY EVENT	2	(2%)	1	(1%)	2 (3%)
	ACROCHORDON EXCISION	0	(0%)	0	(0%)	1 (1%)
	CATARACT OPERATION	1	(1%)	1	(1%)	0 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
 2.) Subjects are only counted once within each body system and preferred term.

Table 1: Summary of Treatment Emergent Adverse Events

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
SURGICAL AND MEDICAL PROCEDURES	EYE LASER SURGERY	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	SKIN LESION EXCISION	0	(0%)	0	(0%)	1	(1%)	1 (0%)
VASCULAR DISORDERS	ANY EVENT	3	(3%)	4	(4%)	1	(1%)	8 (3%)
	HOT FLUSH	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	HYPERTENSION	1	(1%)	2	(2%)	0	(0%)	3 (1%)
	HYPOTENSION	2	(2%)	1	(1%)	0	(0%)	3 (1%)
	ORTHOSTATIC HYPOTENSION	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	WOUND HAEMORRHAGE	0	(0%)	0	(0%)	1	(1%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
 2.) Subjects are only counted once within each body system and preferred term.